Managing Incidental Findings
- An incidental finding (an "incidentaloma") is something you weren't looking for that turns up anyway — the lump in the trunk while you were hunting for car keys.
- The goal is not to chase every one of them. The goal is to sort the boring ones from the ones that deserve a follow-up, using published management guidelines instead of gut feeling.
- Organ-specific frameworks (Fleischner for lung nodules, Bosniak for renal cysts, and others) tell you who needs nothing, who needs a follow-up scan, and who needs a biopsy.
- The single most useful thing you can do is write a clear recommendation in the report, so the finding doesn't get lost or, worse, over-investigated.
You ordered a CT to check for a kidney stone, and the kidney stone is there, sure — but so is a little spot on the liver, a puffy adrenal gland, and a tiny nodule sitting in the bottom of a lung. Welcome to modern imaging, where the scanner sees everything whether you asked it to or not. These uninvited guests are incidental findings, affectionately nicknamed incidentalomas, and learning to manage them is one of the quietest but most important skills in radiology.
Why incidentalomas are a whole topic
Here's the tension. Modern CT and MRI are absurdly detailed — they'll find a 4-millimeter nothing in an organ you weren't even thinking about. The overwhelming majority of these are benign and will never bother anyone. But a small minority are the early whisper of something serious.
If you ignore everything, you'll occasionally miss a real cancer. If you chase everything, you'll subject thousands of healthy people to extra scans, biopsies, anxiety, and the occasional complication — to find one problem. That cascade, where one harmless finding snowballs into a parade of tests, is the thing we're trying to avoid. It even has a nickname: the incidentaloma cascade.
So the field built a compromise: structured, organ-specific guidelines that say, for this finding with these features in this kind of patient, here's the appropriate next step. It takes the panic (and the guesswork) out of it.
The whole game is risk stratification — sorting findings into "leave it alone," "watch it," and "work it up" based on features that actually predict whether it's dangerous. Size, density, growth, and patient risk factors do most of the heavy lifting.
The features that decide everything
You don't memorize a separate rule for every organ from scratch. The same handful of clues keep showing up:
- Size. Bigger findings get taken more seriously. Tiny ones are usually left alone or briefly watched.
- Density / signal. A finding full of fat or simple fluid is reassuring; a solid, enhancing one is more suspicious. (Think of it like a grocery bag: you can often guess what's inside by how heavy and lumpy it feels.)
- Growth over time. A nodule that's been identical for years is basically retired. New or growing is the worrying flavor.
- Patient context. Someone with a known cancer, or a heavy smoker, sits in a higher-risk lane than a healthy 30-year-old, and the guidelines say so explicitly.
The named frameworks (your cheat sheet)
Each organ has its own published system, and they all do the same job: turn features into a recommendation. You don't have to know every threshold by heart — you have to know that the framework exists and to look it up.
| Finding | Framework | What it sorts on |
|---|---|---|
| Pulmonary nodule | Fleischner Society guidelines | Size, solid vs. ground-glass, patient risk |
| Renal cyst / mass | Bosniak classification | Wall, septa, calcification, enhancement |
| Adrenal nodule | Adrenal washout / density | Fat content, density, washout |
| Liver lesion | LI-RADS / liver lesion features | Enhancement pattern, patient risk |
| Thyroid nodule | TI-RADS | Composition, echogenicity, margins |
There are more (the American College of Radiology publishes white papers on incidental findings across many organs), but if you internalize the idea — match the finding to its framework, then follow the recommendation — you've got the concept. The numbers you can always look up.
Always compare with prior imaging before recommending a workup. A "new" nodule that's actually been stable on a scan from three years ago can be dismissed on the spot — and you just saved someone a needless follow-up CT.
Writing the recommendation
A finding you spot but don't act on is half a job. The report is where management actually happens. A good incidental-finding write-up names the finding, its key features, and a specific next step — "follow-up CT in 6–12 months per Fleischner," not a vague "clinical correlation recommended," which everyone has learned to mentally ignore.
The two opposite traps: (1) burying a genuinely worrisome finding in a wall of normal text so nobody acts on it, and (2) recommending aggressive workup for an obviously benign finding and kicking off the cascade. Both are common. The fix is the same: state the finding clearly, apply the right framework, and give a concrete, proportionate recommendation.
For anything urgent or unexpected, the recommendation in the report isn't enough on its own — those belong in a direct conversation with the ordering clinician so it can't slip through the cracks.
The one thing to remember
Incidental findings are inevitable, and most of them are harmless. Your job isn't to fear them or to chase them — it's to triage them. Match the finding to its published framework, factor in the patient and any prior imaging, and write a clear, proportionate recommendation. That's the difference between a finding that gets managed and one that either gets missed or spirals into a pile of unnecessary tests. If you want the bigger picture on ordering studies wisely, it pairs naturally with choosing which test, when.